Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2022/01/25 | 1,291 | 1,351 | 1,183 | 1,203 | -118 | -8.9% | 270,700 |
2022/01/24 | 1,310 | 1,329 | 1,236 | 1,321 | -9 | -0.7% | 198,800 |
2022/01/21 | 1,353 | 1,360 | 1,319 | 1,330 | -50 | -3.6% | 100,300 |
2022/01/20 | 1,442 | 1,501 | 1,350 | 1,380 | -62 | -4.3% | 165,000 |
2022/01/19 | 1,427 | 1,479 | 1,414 | 1,442 | -1 | -0.1% | 116,900 |
2022/01/18 | 1,486 | 1,509 | 1,430 | 1,443 | -42 | -2.8% | 91,600 |
2022/01/17 | 1,547 | 1,554 | 1,474 | 1,485 | -35 | -2.3% | 76,800 |
2022/01/14 | 1,535 | 1,535 | 1,475 | 1,520 | -55 | -3.5% | 125,200 |
2022/01/13 | 1,543 | 1,575 | 1,490 | 1,575 | +11 | +0.7% | 66,500 |
2022/01/12 | 1,560 | 1,600 | 1,528 | 1,564 | +9 | +0.6% | 67,400 |
2022/01/11 | 1,453 | 1,569 | 1,429 | 1,555 | +119 | +8.3% | 138,800 |
2022/01/07 | 1,497 | 1,540 | 1,382 | 1,436 | -14 | -1% | 132,900 |
2022/01/06 | 1,471 | 1,496 | 1,438 | 1,450 | -46 | -3.1% | 98,400 |
2022/01/05 | 1,576 | 1,594 | 1,471 | 1,496 | -82 | -5.2% | 142,200 |
2022/01/04 | 1,515 | 1,589 | 1,515 | 1,578 | +91 | +6.1% | 124,700 |
2021/12/30 | 1,442 | 1,515 | 1,442 | 1,487 | +23 | +1.6% | 111,500 |
2021/12/29 | 1,434 | 1,488 | 1,400 | 1,464 | +16 | +1.1% | 69,400 |
2021/12/28 | 1,515 | 1,550 | 1,430 | 1,448 | -67 | -4.4% | 123,700 |
2021/12/27 | 1,489 | 1,539 | 1,443 | 1,515 | +37 | +2.5% | 109,100 |
2021/12/24 | 1,467 | 1,543 | 1,450 | 1,478 | +29 | +2% | 116,800 |
2021/12/23 | 1,469 | 1,476 | 1,431 | 1,449 | -11 | -0.8% | 43,600 |
2021/12/22 | 1,440 | 1,500 | 1,429 | 1,460 | +10 | +0.7% | 106,900 |
2021/12/21 | 1,396 | 1,460 | 1,351 | 1,450 | +68 | +4.9% | 109,200 |
2021/12/20 | 1,313 | 1,430 | 1,311 | 1,382 | +87 | +6.7% | 156,300 |
2021/12/17 | 1,303 | 1,341 | 1,272 | 1,295 | -42 | -3.1% | 77,300 |
2021/12/16 | 1,399 | 1,406 | 1,321 | 1,337 | -15 | -1.1% | 93,300 |
2021/12/15 | 1,301 | 1,362 | 1,297 | 1,352 | +28 | +2.1% | 51,700 |
2021/12/14 | 1,350 | 1,385 | 1,289 | 1,324 | -33 | -2.4% | 106,700 |
2021/12/13 | 1,481 | 1,491 | 1,338 | 1,357 | -73 | -5.1% | 193,600 |
2021/12/10 | 1,534 | 1,573 | 1,402 | 1,430 | -118 | -7.6% | 212,300 |
2021/12/09 | 1,500 | 1,615 | 1,470 | 1,548 | +35 | +2.3% | 298,100 |
2021/12/08 | 1,285 | 1,578 | 1,285 | 1,513 | +235 | +18.4% | 460,700 |
2021/12/07 | 1,257 | 1,300 | 1,238 | 1,278 | +57 | +4.7% | 79,800 |
2021/12/06 | 1,272 | 1,272 | 1,217 | 1,221 | -64 | -5% | 53,300 |
2021/12/03 | 1,325 | 1,337 | 1,260 | 1,285 | -35 | -2.7% | 76,800 |
2021/12/02 | 1,334 | 1,395 | 1,295 | 1,320 | -32 | -2.4% | 133,500 |
2021/12/01 | 1,255 | 1,380 | 1,203 | 1,352 | +111 | +8.9% | 135,300 |
2021/11/30 | 1,283 | 1,315 | 1,232 | 1,241 | +27 | +2.2% | 74,400 |
2021/11/29 | 1,213 | 1,278 | 1,195 | 1,214 | -26 | -2.1% | 56,200 |
2021/11/26 | 1,254 | 1,272 | 1,207 | 1,240 | -19 | -1.5% | 59,400 |
2021/11/25 | 1,258 | 1,314 | 1,245 | 1,259 | -10 | -0.8% | 50,000 |
2021/11/24 | 1,303 | 1,303 | 1,257 | 1,269 | -48 | -3.6% | 44,200 |
2021/11/22 | 1,321 | 1,323 | 1,271 | 1,317 | -6 | -0.5% | 56,100 |
2021/11/19 | 1,365 | 1,366 | 1,319 | 1,323 | -42 | -3.1% | 29,900 |
2021/11/18 | 1,375 | 1,382 | 1,317 | 1,365 | +2 | +0.1% | 52,700 |
2021/11/17 | 1,410 | 1,418 | 1,351 | 1,363 | -47 | -3.3% | 75,000 |
2021/11/16 | 1,318 | 1,425 | 1,310 | 1,410 | +92 | +7% | 106,500 |
2021/11/15 | 1,261 | 1,336 | 1,230 | 1,318 | +65 | +5.2% | 119,500 |
2021/11/12 | 1,113 | 1,309 | 1,070 | 1,253 | +149 | +13.5% | 208,800 |
2021/11/11 | 1,138 | 1,145 | 1,101 | 1,104 | -28 | -2.5% | 37,700 |
801~
850
件表示中 / 1598件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 45,600円 | - | - | 0.00% | - | 14.13倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
カルナバイオ | 28,000円 | +13.5% | - | 0.00% | - | 2.16倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
DWTI | 10,200円 | -15.1% | - | 0.00% | - | 6.31倍 |
|
三重大学発創薬ベンチャー。プロテインキナーゼ阻害剤開発技術はじめ眼病治療薬開発に集中 |
免疫生物 | 47,400円 | +13.4% | +44.0% | 0.00% | 20.54倍 | 3.30倍 |
|
研究用試薬の製販・受託。遺伝子組み換えカイコの基礎研究は休止し、化粧品等応用開発に移行 |
VIS | 67,300円 | +306.2% | - | 0.00% | 25.98倍 | 1.98倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
市場注目の銘柄
チャート関連のコラム